.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX08_Elotuzumab.Elotuzumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX08_Elotuzumab.Elotuzumab| name: | Elotuzumab | |
| ATC code: | L01FX08 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 5.24 | L |
| clearance: | 0.232 | L/day |
| other parameters in model implementation | ||
Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, used in the treatment of multiple myeloma in combination with other agents. It is FDA-approved for relapsed or refractory multiple myeloma in adult patients.
Pharmacokinetics from adult patients with relapsed or refractory multiple myeloma, population PK estimated after intravenous administration.
Ide, T, et al., & Vezina, HE (2021). Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein. Journal of clinical pharmacology 61(1) 64–73. DOI:10.1002/jcph.1698 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32656777
Zonder, JA, et al., & Singhal, AK (2012). A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120(3) 552–559. DOI:10.1182/blood-2011-06-360552 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22184404